According to a new report, published by KBV Research, The Global Artificial Intelligence In Precision Medicine Market size is expected to reach USD 31,628.7 million by 2033, rising at a market growth of 37.8% CAGR during the forecast period.
Healthcare organizations are increasingly using artificial intelligence to interpret complex genomic, clinical, imaging, pathology, and real-world datasets in ways that support more individualized care. AI is helping clinicians and researchers improve patient stratification, biomarker identification, disease diagnosis, therapy selection, and treatment planning while also supporting faster drug discovery and clinical research. Growing use of sequencing, digital pathology, wearable data, and multi-omics platforms is expanding the volume of information available for precision medicine workflows.
The Software segment acquired the highest revenue share in the Global Artificial Intelligence In Precision Medicine Market by Component in 2025, thereby, achieving a market value of USD 12,970.9 million by 2033. AI software provides the analytical foundation for predictive modeling, clinical decision support, biomarker discovery, patient stratification, and interpretation of complex biological datasets. These platforms can combine genomic, imaging, pathology, and clinical information to support more personalized treatment decisions. Growing integration with healthcare workflows and research environments is improving practical adoption across hospitals, pharmaceutical companies, and biotechnology firms. Advances in AI models and data-processing capabilities are also expanding platform functionality.
The Deep Learning segment acquired the highest revenue share in the Global Artificial Intelligence In Precision Medicine Market by Technology in 2025, thereby, achieving a market value of USD 10,071.0 million by 2033. Deep learning is widely applied where large and complex datasets require advanced pattern recognition, including medical imaging, genomics, pathology, and multi-omics analysis. These models can identify subtle relationships across biological and clinical information that may be difficult to detect through conventional analytical approaches. Their use is expanding across disease classification, biomarker identification, treatment prediction, and research workflows. Increasing availability of high-quality healthcare datasets is further strengthening model development.
The Oncology segment acquired the highest revenue share in the Global Artificial Intelligence In Precision Medicine Market by Therapeutic Application in 2025, thereby, achieving a market value of USD 9,347.7 million by 2033. Oncology remains a major area for AI-enabled precision medicine because cancer care increasingly depends on genomic profiling, tumor characterization, biomarker discovery, liquid biopsy, and companion diagnostics. AI platforms help clinicians and researchers analyze complex tumor data and identify treatment-relevant patterns more efficiently. These capabilities are also supporting patient stratification and personalized therapy selection across precision oncology programs. Growing use of digital pathology and multimodal datasets is further expanding AI applications in cancer care.
The North America segment recorded the highest revenue share in the Global Artificial Intelligence In Precision Medicine Market by Region in 2025, thereby, achieving a market value of USD 16,469.1 million by 2033. Strong healthcare data infrastructure, advanced biopharma activity, substantial AI investment, and early adoption of precision oncology and clinical decision-support platforms are supporting regional demand. Hospitals, research institutions, pharmaceutical companies, and technology developers are increasingly collaborating on AI-enabled diagnostic, genomic, and therapeutic applications. Expanding use of multimodal healthcare data is also strengthening opportunities for advanced model development and clinical deployment.
By Component
By Technology
By Therapeutic Application
By Geography
Unique Offerings
